ORIC-533 is an orally active, highly selective, AMP-competitive CD73 inhibitor that potently blocks adenosine production with sub-nanomolar affinity (Ka 0.03 nM). In multiple myeloma, ORIC-533 restores and enhances the cytotoxicity of the immune system against tumor cells through multiple immunological mechanisms, including reversing the immunosuppressive microenvironment, inducing immunogenic cell death, and activating dendritic cells, T cells and NK cells, with no direct toxicity to normal cells. The combination of ORIC-533 with daratumumab (HY-P9915) synergistically enhances anti-tumor efficacy, significantly increases intratumoral CD8+ T cell infiltration and inhibits tumor growth in vivo[1][2].
Molecular Weight:
605.93
CAS Number:
[2641306-62-7]
Formula:
C20H29ClN9O9P
Target:
CD73
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
